Abstract

Introduction: Choroid plexus carcinoma (CPC) is a rare central nervous system neoplasm derived from the choroid plexus epithelium. CPCs are challenging to surgically resect due to their intraventricular location and high vascularity. Tumor recurrence and dissemination are frequently seen with CPC. Due to the malignant nature of these tumors, the prognosis is poor with a five year survival rate of approximately 40%. Case Description: The authors report a pediatric patient with a CPC (WHO grade III) with oncocytic changes, who survived for seven years after her initial diagnosis. A 14-month-old female presented to the emergency department with a sudden onset change in mental status following a fall. Imaging revealed a hemorrhagic, left intraventricular heterogeneous tumor. The patient underwent a left parietal craniotomy and gross tumor resection. Pathological findings were consistent with a malignant CPC. Her treatment regimen included four cycles of etoposide, Temodar, Cytoxan and vincristine, two cycles of oral etoposide and temozolomide with vincristine, in addition to a stem cell harvest. Recurrence of our patient’s disease led to two subsequent gross total resections. This patient was in the minority who survived greater than five years with this tumor type. Conclusion: Gross total resection is the goal, and pharmacologic intervention including chemotherapy and radiation therapy remains controversial, as this treatment is not curative. We would like to share this unusual case with the medical community to increase clinical understanding in the management and treatment of this malignant tumor.

Highlights

  • Choroid plexus carcinoma (CPC) is a rare central nervous system neoplasm derived from the choroid plexus epithelium

  • Choroid plexus tumors (CPTs) are rare, intraventricular neoplasms that originate from the epithelial cells of the choroid plexus [1,2,3,4]

  • The World Health Organization (WHO) has classified a CPC as a WHO grade III, and prognosis is poor with a five year survival rate of approximately 40% [2,8]

Read more

Summary

Conclusion

CPC is an aggressive tumor, and prognosis is poor. Despite four cycles of VP-16, Temodar, Cytoxan and vincristine, two cycles of oral etoposide and temozolomide with vincristine, our patient’s disease returned about four years after the completion of therapy. This pediatric patient was in the minority who survived longer than five years with a CPC (WHO grade III), which has a five year survival rate of only 40% [2]. We would like to share this unusual case with the medical community to increase clinical understanding in the management and treatment of this rare, malignant tumor

Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call